DexCom, Inc. vs iShares MSCI Malaysia ETF — how do they compare? DexCom, Inc. trades at $90.57 (market cap $33.79B), while iShares MSCI Malaysia ETF trades at $28.29. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | EWM | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $30.42 |
52-Week Low | $54.84 | $24.73 |
Enterprise Value | $33.24B | — |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
EWM, the iShares MSCI Malaysia ETF, trades at $28.29, up 0.89% today. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The ETF is heavily weighted in Financials (54%) and Industrials (21%), positioning it to benefit from Malaysia's data center expansion and semiconductor initiatives. A dividend of $0.57 per share is scheduled for payment on June 18, 2026.
The outlook for EWM hinges on Malaysia's economic growth drivers, including tourism and energy sector developments. Risks include regional volatility and global macroeconomic pressures. Analyst sentiment is mixed, with technical weakness offset by thematic growth opportunities in Southeast Asia.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →